Biomere supports preclinical drug developers by generating PK/PD data needed to guide dosing levels and routes, evaluate exposure-response, support early toxicology decisions, and move confidently toward IND-enabling studies.
When every study decision matters, you need more than data. You need a responsive scientific partner who can help design the right study, execute efficiently, and interpret results in the context of your development goals. Biomere’s scientists work closely with clients and frequently host clients on-site to observe and participate in procedures. Our transparent approach ensures clients know study status in real time and are aware of challenges and mitigations immediately.
Generate exposure, response, and biomarker data to inform dose selection and development planning.
Use early PK/PD and toxicology insights to identify risks before committing to larger IND-enabling programs.
Collaborate with a high-touch CRO team that understands complex preclinical development requirements.
Simplify complex programs with coordinated study execution, sample handling, bioanalysis, and interpretation.
Biomere provides flexible PK/PD support across drug modalities and development stages to translate preclinical findings into actionable insights for efficacy and safety study planning.
Understand absorption, biodistribution, metabolism, exposure, clearance, and bioavailability.
Measure biological response, target engagement, biomarkers, and dose-response relationships.
Support drug quantification, biomarker analysis, LC-MS/MS workflows, and assay-driven insights.
Generate early toxicology data across small molecules, biologics, cell therapies, and gene therapy programs.
Whether you are preparing for IND-enabling studies, evaluating a new modality, comparing dose levels, or looking for a more responsive CRO partner, Biomere can help you generate decision-ready data.
Talk with Biomere’s scientific team about your program goals, timelines, model requirements, dosing strategy, and study design needs.
